Key Highlights for Investors:
- Ironwood Pharmaceuticals (IRWD, Financial) faces a setback with FDA requiring another phase 3 trial for apraglutide.
- The stock dipped 31%, making analysts' target prices and recommendations crucial for investors.
- With an estimated GF Value suggesting an 864.49% upside, IRWD remains a stock to watch.
Ironwood Pharmaceuticals (IRWD) recently experienced a significant development regarding its treatment for short bowel syndrome. The FDA has mandated an additional phase 3 trial for apraglutide, prompting Ironwood to seek strategic advice from Goldman Sachs. Following this announcement, IRWD shares saw a steep decline of 31%, accompanied by a surge in trading activity.
Wall Street Analysts Forecast
According to the insights of six analysts, the average one-year price target for Ironwood Pharmaceuticals Inc (IRWD, Financial) stands at $6.12. Price expectations span from a high of $14.00 to a low of $0.70, suggesting a potential upside of 710.37% from the current price of $0.75. Investors can explore more detailed estimates on the Ironwood Pharmaceuticals Inc (IRWD) Forecast page.
The consensus from seven brokerage firms positions Ironwood Pharmaceuticals Inc (IRWD, Financial) at an average recommendation of 2.4, indicating an "Outperform" status. This rating emerges from a scale where 1 signifies a "Strong Buy" and 5 suggests a "Sell".
Further reinforcing the optimistic outlook, GuruFocus estimates suggest a GF Value of $7.28 for Ironwood Pharmaceuticals Inc (IRWD, Financial) in the next year, signaling a substantial upside potential of 864.49% from its current trading price of $0.7548. The GF Value is derived from historical trading multiples, past business growth, and projections of the company's future performance. For additional data, please visit the Ironwood Pharmaceuticals Inc (IRWD) Summary page.
